Promotions & Moves

Bioclinica Appoints CEO

Hubbard to retire, Herron assumes role of CEO

By: Kristin Brooks

Managing Editor, Contract Pharma

David Herron has been appointed chief executive officer of Bioclinica, effective January 2, 2018. This follows the planned retirement of current chief executive officer, John Hubbard, Ph.D., who will remain as a non-executive director on the Bioclinica board.

Mr. Herron has more than 10 years of experience at Bioclinica leading the company’s Medical Imaging business, where he integrated three of the industry’s leading medical imaging companies (Bioclinica, Corelab Partners, and Synarc) into one service provider.

Recently Mr. Herron assumed the additional responsibility of leading Bioclinica’s technology-focused eHealth segment. In his new role, his oversight will extend to Bioclinica’s network of investigator sites and patient recruitment businesses.

Dr. John Hubbard, current chief executive officer of Bioclinica said, “It has been a privilege to serve as Chief Executive of Bioclinica for the past three years, however, now is the right time for me to take on a new role and welcome David to the Board. This key transition has been core in our succession planning process. I’ve seen David successfully assume greater responsibility in the organization where he’s been integral in Bioclinica’s transformation over the last four years. I have every confidence in his ability to lead Bioclinica in the next phase of growth.”

Mr. Herron said, “I would like to thank John for his significant contribution as Chief Executive of Bioclinica for the last three years and I look forward to continue working with him in his new capacity as non-Executive Director. I am excited by the prospect of continuing to build and enhance Bioclinica’s technology and service offering and working to help our clients improve clinical trial outcomes in the years ahead.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters